Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ensysce Biosciences, Inc. (ENSC : NSDQ)
 
 • Company Description   
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.53 Daily Weekly Monthly
20 Day Moving Average: 875,502 shares
Shares Outstanding: 34.56 (millions)
Market Capitalization: $18.20 (millions)
Beta: 0.53
52 Week High: $17.12
52 Week Low: $0.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -50.32% -45.60%
12 Week -51.69% -45.70%
Year To Date -88.80% -86.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7946 IVANHOE AVENUE SUITE 201
-
LA JOLLA,CA 92037
USA
ph: 858-263-4196
fax: -
shannon@mzgroup.us http://www.ensysce.com
 
 • General Corporate Information   
Officers
Lynn Kirkpatrick - President; Chief Executive Officer and Director
Bob Gower - Chairman
David Humphrey - Chief Financial Officer; Secretary and Treasurer
Andrew Benton - Director
William Chang - Director

Peer Information
Ensysce Biosciences, Inc. (CORR.)
Ensysce Biosciences, Inc. (RSPI)
Ensysce Biosciences, Inc. (CGXP)
Ensysce Biosciences, Inc. (BGEN)
Ensysce Biosciences, Inc. (GTBP)
Ensysce Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 293602108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 34.56
Most Recent Split Date: (:1)
Beta: 0.53
Market Capitalization: $18.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 15.17
Price/Cash Flow: -
Price / Sales: 4.69
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 55.56%
Sales Growth
vs. Year Ago Period: 140.24%
vs. Previous Quarter: -63.12%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -484,682.75
ROA
03/31/22 - -289.01
12/31/21 - -247.16
09/30/21 - -270.56
Current Ratio
03/31/22 - 1.32
12/31/21 - 0.95
09/30/21 - 1.27
Quick Ratio
03/31/22 - 1.32
12/31/21 - 0.95
09/30/21 - 1.27
Operating Margin
03/31/22 - -887.38
12/31/21 - -845.19
09/30/21 - -686.96
Net Margin
03/31/22 - -788.03
12/31/21 - -845.07
09/30/21 - -680.67
Pre-Tax Margin
03/31/22 - -751.42
12/31/21 - -825.43
09/30/21 - -691.08
Book Value
03/31/22 - 0.03
12/31/21 - -0.34
09/30/21 - -0.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 1.43
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - 58.82
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©